Navigation Links
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that its fourth quarter and year-end 2010 financial results will be released on Friday, February 25, 2011, at 7:00 a.m. Eastern Time. Following the announcement, John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call and webcast at 9:00 a.m. Eastern Time to review the Company's financial results and recent business developments.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 45733606. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on Friday, February 25, 2011, through 11:59 p.m. Eastern Time on March 11, 2011 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 45733606.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Closes Sale of $230 Million in Convertible Senior Notes
2. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
3. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
5. Savient Pharmaceuticals Announces Search for CEO
6. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
8. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
9. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
10. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
11. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):